In our phase @ , randomized , double-blind , multicenter study involving patients with progressive thyroid cancer that was refractory to iodine-@ , we randomly assigned @ patients to receive lenvatinib ( at a daily dose of @ mg per day in @-day cycles ) and @ patients to receive placebo .